Shandong Weigao Orthopaedic Device Co., Ltd. (Weigao Orthopaedic) (688161)

Individual Stock Analysis Report　|　Industry: Orthopaedic Medical Devices　|　Report Date: September 13, 2026　|　As of the close on September 11, 2026; prices, trading volumes and technical indicators may differ across data platforms. Moving averages, MACD, RSI and Bollinger Bands are based on unadjusted daily data.

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

Weigao Orthopaedic generated revenue of RMB 1.523 billion in 2025, up 4.82% year on year, and net profit attributable to shareholders of RMB 269 million, up 20.06% year on year. Profit growth was significantly higher than revenue growth. However, in the first half of 2026, revenue was RMB 704 million and net profit attributable to shareholders was RMB 132 million, down 4.93% and 6.85% year on year, respectively. Non-recurring-item-excluded net profit attributable to shareholders and net cash flow from operating activities also declined by 7.28% and 24.59%, respectively, indicating that earnings recovery continues to face near-term pressure.

The company’s revenue mix is shifting from traditional orthopaedic implants toward higher-margin businesses. In 2025, revenue from orthopaedic implants and consumables was RMB 962 million, down 3.76% year on year, reflecting a “volume-for-price” pattern in which sales volume rose 7.22% while revenue declined. Revenue from orthopaedic intelligent equipment and consumables rose 25.68% year on year, while revenue from functional repair and tissue regeneration rose 19.54%, with the latter achieving a gross margin of 83.08%. Product-mix upgrading, expansion of the tissue-repair business, and growth in intelligent equipment and minimally invasive spine products are the main potential drivers of subsequent earnings improvement.

The company continues to rely primarily on distributor channels. In 2025, distributor revenue accounted for approximately 91.3% of revenue from principal operations. Terminal prices, hospital order volumes, distribution systems and volume-based procurement policies have a significant impact on operating results. Supplier and customer concentration declined in some respects from 2024. At the end of 2025, receivables from the top five customers accounted for 29.41% of total accounts receivable, while days sales outstanding declined to approximately 65.3 days, indicating improved collection efficiency. However, channel credit terms, rebates and post-procurement price-management pressures remain.

As of September 11, 2026, the company’s share price closed at RMB 21.65, with a price-to-book ratio of approximately 2.06x and a dynamic price-to-earnings ratio of approximately 32x, down approximately 41.1% from the 52-week high. Technically, the share price was below the MA5, MA10 and MA20. MACD was slightly weak. RMB 21.35–21.50 is the support-monitoring zone, while RMB 22.10–22.80 is the main resistance zone. No clear medium-term trend has yet formed, and price performance remains dependent on earnings delivery and changes in market liquidity.

2. Company Overview

2.1 Basic Information

2.2 Principal Businesses and Product Portfolio

• Orthopaedic implants and consumables: Includes spine, trauma, joint, sports medicine and craniomaxillofacial surgery products. Key products include spinal fixation systems, interbody fusion cages, locking bone plates, intramedullary nails, joint prostheses, anterior cruciate ligament reconstruction systems, meniscus repair systems and 3D-printed personalized cranial-defect repair plates. Revenue was RMB 962 million in 2025, approximately 63.8% of revenue from principal operations and down 3.76% year on year; sales volume was 6.2587 million units, up 7.22% year on year.
• Orthopaedic intelligent equipment and consumables: Includes orthopaedic endoscopes, energy platforms, power systems and surgical instruments, vertebroplasty systems, orthopaedic interventional puncture needles, minimally invasive spine products and related equipment. Through equity investments in or affiliated companies, the company is also developing digital orthopaedics businesses such as weight-bearing cone-beam CT, orthopaedic surgical robots and intelligent navigation. Revenue was RMB 113 million in 2025, approximately 7.5% of revenue from principal operations and up 25.68% year on year, with a gross margin of 54.68%.
• Functional repair and tissue regeneration: Includes platelet-rich plasma preparation kits, closed-wound negative-pressure drainage kits, self-setting calcium phosphate artificial bone and rhBMP-2-loaded bioactive products, used in bone-defect filling, spinal fusion, joint fusion, craniomaxillofacial and oral-maxillofacial surgery, among other applications. Revenue was RMB 430 million in 2025, approximately 28.5% of revenue from principal operations and up 19.54% year on year, with a gross margin of 83.08%.
• Manufacturing and R&D capabilities: The company uses machining, CNC processing, 3D printing, automated production and lean manufacturing processes. As of the end of 2024, the company and its subsidiaries held 301 Class I product filing certificates, 41 Class II medical-device registration certificates and 158 Class III medical-device registration certificates, and had 371 patents in total.

2.3 Position in the Upstream and Downstream Value Chain and Cost-Profit Structure

Weigao Orthopaedic operates in the midstream-to-downstream segment of the orthopaedic medical-device value chain. The company purchases medical metals, polymer materials, ceramics and joint-prosthesis blanks from upstream suppliers, and uses precision processing, surface treatment, 3D printing, product registration and quality control to produce spine, trauma, joint, sports-medicine, intelligent-equipment and tissue-repair products. Downstream customers mainly include hospitals, medical institutions, orthopaedic consumables distributors and delivery companies.

• Major procurement items include medical titanium, special stainless steel, cobalt-chromium-molybdenum alloys, ultra-high-molecular-weight polyethylene, implant-grade PEEK, ceramic femoral heads and liners, and joint-prosthesis blanks. Key materials collectively account for approximately 75% of raw-material purchases.
• Purchases from the top five suppliers amounted to RMB 144 million in 2025, accounting for 40.54% of total annual purchases. Purchases from related parties amounted to RMB 55.9269 million, accounting for 15.71% of total annual purchases. The top five suppliers accounted for 57.04% of total purchases in 2024. According to the disclosed meeting minutes, supplier concentration declined from 2024.
• Progress in localizing key imported raw materials should improve supply-chain stability and reduce procurement risk. However, medical titanium, implant-grade PEEK, ceramics and materials related to joint prostheses are subject to high technical and certification requirements, and some high-end suppliers will be difficult to replace in the short term.
• The company has relatively strong bargaining power when procuring ordinary machined components and certain standardized materials. Its bargaining power is relatively limited for high-end implant-grade materials, special ceramics, high-performance polymers and joint-prosthesis blanks, with some materials being more strongly controlled by technology-oriented suppliers. Raw-material price increases are not the sole driver of profit volatility; volume-based procurement price cuts and product-mix changes have a greater impact.
• Downstream customers mainly include hospitals, medical institutions, orthopaedic consumables distributors and delivery companies. In 2025, distributor revenue was RMB 1.390 billion, delivery revenue was RMB 88 million and direct-sales revenue was RMB 43 million. Distribution remained the core sales channel, accounting for approximately 91.3% of revenue from principal operations.
• Sales to the top five customers amounted to RMB 255 million in 2024, accounting for 17.55% of total annual sales. The largest individual customer accounted for 4.76% of sales. The meeting minutes therefore concluded that the company was not materially dependent on any single customer. This sales-concentration data is for 2024; the meeting minutes did not provide the 2025 proportion of sales to the top five customers. The latest annual report should prevail.
• At the end of 2025, receivables from the top five customers accounted for 29.41% of total accounts receivable, compared with 44.05% in 2024. This is an accounts-receivable concentration measure and should not be directly conflated with the 17.55% share of sales attributable to the top five customers in 2024.
• Hospitals and the medical-insurance payment system are the industry’s key downstream channels. Product prices are affected by national and interprovincial alliance volume-based procurement, medical-insurance payment standards, hospital order volumes and delivery systems. Volume-based procurement can expand terminal coverage and purchasing volumes, but compresses product prices and channel profits. The distributor model also involves pressure from credit terms, rebates, professional services and channel price management.
• The company uses a relatively complete product portfolio, supply capabilities, clinical-support services and cross-selling among products to improve hospital coverage and customer retention. However, its product pricing power has weakened materially compared with the period before volume-based procurement.
• At the end of 2025, receivables from the top five customers were RMB 96.2096 million, or 29.41% of total accounts receivable, down from 44.05% in 2024. Days sales outstanding were approximately 65.3 days, down from approximately 72.1 days in 2024, indicating improved collection efficiency. Hospitals and distributors continue to require credit terms and channel services, which occupy working capital. Selling expenses declined and operating cash flow improved in 2025, but this does not fully rule out fluctuations in payment cycles during the stages of volume-based procurement and channel adjustments.
• Regarding supplier concentration, purchases from the top five suppliers accounted for 40.54% of total purchases in 2025, compared with 57.04% in 2024. Regarding customer sales concentration, only the 2024 figure of 17.55% for the top five customers was disclosed; the corresponding 2025 figure was not provided. Regarding customer receivables concentration, the top five customers accounted for 29.41% at the end of 2025, compared with 44.05% in 2024. The above data come from annual reports and related disclosures cited in the meeting minutes. Sales concentration and receivables concentration use different definitions, and the 2025 customer sales-concentration data are unavailable. The latest annual report should prevail.

Weigao Orthopaedic is not a single high-margin upstream-materials company. Rather, it is an integrated orthopaedic platform based on the scaled manufacturing of orthopaedic implants and extending into intelligent equipment and tissue regeneration, operating in the midstream manufacturing segment. Earnings improvement depends mainly on the expansion of high-margin tissue-repair and biomaterials businesses, growth in minimally invasive spine and intelligent equipment products, product-mix upgrades, localization of raw materials, manufacturing-efficiency improvements, and whether a better balance can be achieved between post-procurement product prices and sales volumes.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

First-half 2026 data are from the 2026 interim report, which was unaudited; full-year 2025 data are from the audited annual report. Non-recurring-item-excluded net profit attributable to shareholders was RMB 125.92 million in the first half of 2026, down 7.28% year on year, while net cash flow from operating activities was RMB 140.42 million, down 24.59% year on year. For full-year 2025, non-recurring-item-excluded net profit attributable to shareholders was RMB 254.67 million, up 20.77% year on year, and net cash flow from operating activities was RMB 415.42 million, up 51.51% year on year. Basic EPS was RMB 0.33 in the first half of 2026 and RMB 0.68 for full-year 2025.

The company achieved moderate revenue growth and faster profit growth in 2025, with improved earnings quality and operating cash flow. However, revenue, net profit attributable to shareholders, non-recurring-item-excluded net profit attributable to shareholders and operating cash flow all declined year on year in the first half of 2026. The main factors were temporary fluctuations in domestic terminal clinical surgery volumes, intensified competition, volume-based procurement of orthopaedic consumables and product-mix changes. The revenue decline accelerated in the second quarter compared with the first quarter, while the profit decline narrowed relatively. Operating costs increased 3.38% year on year in the first half of 2026, putting pressure on overall profitability.

3.2 Earnings Forecast

As of September 3, 2026, the iFinD earnings-forecast page indicated that six institutions had issued forecasts over the previous six months, although the publicly expanded institution-level details mainly showed four institutions. The aggregate figures may include other institutions whose information was not fully displayed. The main publicly verifiable forecast reports were dated between April 5 and April 30, 2026, before the interim report was released on August 26, 2026, creating a risk of forecast lag. The publicly listed institutions included Northeast Securities, Guosen Securities, Tianfeng Securities and Soochow Securities.

3.3 Valuation and Institutional Ratings

As of September 11, 2026, the company’s closing price was approximately RMB 21.50. Based on total share capital of 400 million shares, market capitalization was approximately RMB 8.6 billion. Based on net assets attributable to shareholders of RMB 4.19527 billion at the end of the 2026 interim reporting period, book value per share was approximately RMB 10.49, corresponding to a price-to-book ratio of approximately 2.05x. Based on full-year 2025 basic EPS of RMB 0.68, the static P/E ratio was approximately 31.6x. Some market-data terminals showed a static P/E of approximately 32.2x and a dynamic P/E of approximately 32.7x around the same date. Differences may reflect the price timestamp, treatment of repurchased shares and profit definitions.

Based on first-half 2026 net profit attributable to shareholders of RMB 132.23 million, first-half 2025 net profit attributable to shareholders of RMB 141.96 million and full-year 2025 net profit attributable to shareholders of RMB 268.64 million, the estimated trailing-12-month net profit attributable to shareholders was approximately RMB 258.92 million. TTM EPS was approximately RMB 0.647, corresponding to a TTM P/E of approximately 33.2x. Different terminals may show approximately 33–35x. Based on consensus EPS forecasts, the current share price corresponds to forecast P/E ratios of approximately 26.5x, 22.2x and 19.0x for 2026, 2027 and 2028, respectively. If 2026 net profit attributable to shareholders reaches the institutional average forecast of approximately RMB 322 million, the valuation based on actual earnings would decline. However, with first-half 2026 net profit down 6.85% year on year, whether full-year growth can reach the approximately 19.9% projected by institutions depends on recovery in surgery volumes in the second half, a reduced impact from volume-based procurement, growth in sports medicine and minimally invasive orthopaedic businesses, and the results of acquisition integration. Institutional views are generally positive, with ratings mainly ranging between “Buy” and “Outperform.” The only clearly verifiable target price is Orient Securities’ RMB 36.19; target prices were not publicly disclosed or could not be verified for the other reports, so an average institutional target price should not be estimated. Key risks include renewal and pricing changes in orthopaedic volume-based procurement, the pace of recovery in domestic clinical surgery volumes, product-mix changes, overseas business growth, integration of acquired assets, and changes in accounts receivable and operating cash flow.

4. Recent News and Announcements

4.1 Weigao Orthopaedic to Participate in STAR Market Medical-Device Industry Collective Earnings Briefing

The company announced on September 9, 2026, that it plans to participate in the “2026 First-Half Collective Earnings Briefing for the Medical Device and Medical Equipment Industry on the STAR Market,” organized by the Shanghai Stock Exchange, from 15:00 to 17:00 on September 17, 2026. The meeting will cover first-half 2026 operating results, financial condition and issues of interest to investors. As of September 12, 2026, the meeting had not yet taken place, and no new operating data or formal capital-markets announcement had been issued.

4.2 No New Buyback, Earnings-Preview, Share-Reduction or Acquisition Announcement Identified in September 2026

As of September 12, 2026, the main publicly searchable announcement in September 2026 was the September 9 earnings-briefing announcement. No newly disclosed 2026 third-quarter earnings preview, new share-repurchase plan or progress update, shareholding increase or reduction by the controlling shareholder or actual controller, major asset acquisition or disposal, or administrative regulatory measure or disciplinary action was identified. This result is based on public searches as of September 12, 2026, and does not mean that the company will not disclose such matters in the future.

4.3 Revenue and Net Profit Declined Year on Year in the First Half of 2026

The company released its 2026 interim report on August 26, 2026. First-half 2026 revenue was RMB 704.4243 million, down 4.93% year on year; net profit attributable to shareholders was RMB 132.2315 million, down 6.85% year on year; and net profit attributable to shareholders after excluding the impact of share-based compensation expenses was RMB 145.6457 million, down 4.64% year on year. The data were as of June 30, 2026, were unaudited and did not represent the latest operating data as of September 12, 2026. Traditional orthopaedic implants continued to face pressure from volume-based procurement, industry competition and product prices. The company is developing sports medicine, minimally invasive spine, intelligent equipment and active-energy equipment businesses.

4.4 Company Proposes an Interim Dividend for 2026

The company proposes to pay a cash dividend of RMB 0.90 per 10 shares to all shareholders, based on total share capital after deducting shares held in the repurchase-specific securities account. The total expected cash dividend is RMB 35,755,751.16, equivalent to approximately 27.04% of first-half 2026 net profit attributable to shareholders. As of June 30, 2026, the repurchase-specific securities account held 2,713,876 shares, or approximately 0.68% of total share capital. These shares will not participate in the profit distribution. The dividend plan remains subject to implementation in accordance with the announcement. Details of implementation and the record date are pending subsequent announcements.

4.5 Approximately 2.71 Million Shares Repurchased as of June 30, 2026

As of June 30, 2026, the company had repurchased 2,713,876 shares through the Shanghai Stock Exchange system via centralized bidding, representing 0.68% of total share capital. The shares are held in a repurchase-specific securities account and do not carry voting or profit-distribution rights. As of September 12, 2026, publicly searchable materials did not show any further disclosure of new repurchase volumes or a change in the purpose of the repurchased shares.

4.6 2025 Restricted-Stock Incentive Plan Enters First Vesting Period

On August 26, 2026, the company disclosed announcements regarding satisfaction of the vesting conditions for the first vesting period of the first grant under the 2025 restricted-stock incentive plan, adjustment of the grant price and cancellation of some granted but unvested restricted shares. The company is advancing the first vesting of the equity incentive plan and clearing outstanding incentive shares. The specific vesting quantity, adjustment to the grant price and number of cancelled shares are subject to the company’s relevant special announcements.

4.7 Company Proposes to Use up to RMB 3 Billion of Idle Internal Funds for Cash Management

The company disclosed on August 26, 2026, that it proposes to use up to RMB 3 billion of partially idle internal funds for cash management, provided that daily operations, fund security and development of the principal business are not affected. This is a fund-utilization arrangement and does not represent a new external investment or industrial acquisition. The announcement did not indicate that the full RMB 3 billion would actually be used. The actual investment size, product term and yield will depend on subsequent specific transactions.

4.8 Certain Fundraising Projects Postponed and Subject to Reassessment

On August 26, 2026, the company disclosed the postponement and reassessment of certain fundraising investment projects, together with related verification opinions. Construction of the R&D center and other fundraising projects had previously been adjusted, and some of the funds were used to acquire equity in and inject capital into Suzhou Jisibai’er Medical Technology Co., Ltd. Going forward, investors should monitor the impact of the postponed projects on new-product registration, R&D commercialization and capacity planning, as well as goodwill and continued losses associated with the acquisition target.

4.9 Some Shareholders Reduced Their Holdings in the First Half of 2026, with No Apparent Change in Control

As of June 30, 2026, Shandong Financial Investment Group Co., Ltd. held 7,274,617 shares, down 4,232,154 shares from the previous period; Weihai Yongyao Trading Center (Limited Partnership) held 3,450,750 shares, down 2,179,250 shares from the previous period. Public materials did not indicate that these shareholders belonged to the company’s controlling shareholder or actual-controller system. Weigao Group Medical Polymer Products Co., Ltd., Weigao International Medical Co., Ltd., Weigao Group Co., Ltd. and Weihai Hongyangrui Information Technology Center remained entities controlled by actual controller Chen Xueli. No disclosure indicated a change in control during the reporting period. The above data alone cannot determine the specific reduction dates, prices or transaction methods.

4.10 Number of Shareholders Increased as of June 30, 2026

Public market-announcement information indicated that the number of A-share shareholders was 10,119 as of June 30, 2026, an increase of 516 from March 31, 2026, or approximately 5.37%. This data only reflects a change in the number of shareholders and cannot directly be used to infer capital flows, institutional buying or improvement in the shareholder structure.

4.11 Company Responded to the Shanghai Stock Exchange’s Inquiry Letter on the 2025 Annual Report

The company disclosed its response to the inquiry letter on the 2025 annual report on July 11, 2026. The response covered the Jisibai’er acquisition, performance commitments of Shandong Weigao New Life Medical Devices Co., Ltd., the repurchase obligation for the minority interest in Zhejiang Quantum Medical Devices Co., Ltd. and goodwill impairment testing. The company stated that Jisibai’er met the closing conditions and obtained control on February 1, 2026, and was included in the consolidated statements. Jisibai’er recorded a loss of RMB 4.3466 million in the first three quarters of 2025, and its impact on the company’s net profit was negative RMB 3.4541 million in the first half of 2026. The inquiry and response do not indicate that the company was subject to administrative penalties, but they reflect the exchange’s attention to the operating quality of the acquisition target, goodwill impairment risk and fulfillment of performance commitments.

4.12 Acquisition of 55% of Suzhou Jisibai’er and Capital Increase Completed and Consolidated

In December 2025, the company disclosed a plan to change part of its fundraising projects, acquire equity in Suzhou Jisibai’er Medical Technology Co., Ltd. and inject capital into it. The company planned to purchase part of the original shareholders’ equity for RMB 66.46 million and subscribe for newly issued registered capital for RMB 20 million, representing a total investment of RMB 86.46 million. After completion, the company held 55% of Jisibai’er. Jisibai’er is mainly engaged in products and technologies related to minimally invasive orthopaedics and active-energy equipment. It met the closing conditions on February 1, 2026, and was included in the consolidated scope. In the first half of 2026, the target’s impact on the company’s net profit was negative RMB 3.4541 million. The strategic initiative has been implemented, but its contribution to profitability has not yet emerged.

4.13 No New Major Acquisition Identified as of September 12, 2026

As of September 12, 2026, public searches did not identify any newly disclosed major equity acquisition, asset disposal, issuance of shares to purchase assets or new industrial-fund investment project by Weigao Orthopaedic in September 2026. The Jisibai’er acquisition remains the company’s main recent M&A transaction. Its subsequent narrowing of losses, business synergies, goodwill impairment and earnings improvement require continued monitoring.

5. Share-Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of September 11, 2026, Weigao Orthopaedic closed at RMB 21.65, down 4.46% on the day. The closing price fell below the MA5, MA10 and MA20, weakening the short-term price structure. The share price was close to the Bollinger lower band at RMB 21.46, but RSI had not entered an extreme oversold range and MACD showed only a slight negative histogram. The current situation is closer to a period of short-term weakness and support monitoring than to a clearly established medium-term trend. RMB 21.35–21.50 is the first support-monitoring zone, while RMB 22.10–22.80 is the main resistance zone. If support fails, attention should turn to RMB 19.80–20.20. Turnover was approximately RMB 46 million and the turnover ratio was 0.53%. Main funds remained in cumulative net inflow over the past 10 trading days, but recorded a net outflow on September 11 amid a high-volume decline, indicating marginally weaker liquidity. Concentration among the top 10 free-float shareholders was high, while the visible holdings of public funds and insurance funds among the top 10 shareholders as of March 31, 2026 were low. Actual active trading liquidity was therefore relatively limited, and prices may be sensitive to small amounts of trading in a low-turnover environment.

5.3 Short-Term Outlook (Next Week, Scenario Analysis for Reference Only)

⚠️ Risk Warning: The following is a subjective scenario analysis based on closing data, historical prices and technical indicators as of September 11, 2026. It does not constitute investment advice or a definitive forecast of future performance.

① Key Technical Levels

② Scenarios for the Next Week (Subjective Weights, Not Statistical Probabilities)

• Range-bound consolidation (relatively high heuristic subjective weight, approximately 50%–60%; not a statistical probability): Focus on a price range of RMB 21.35–22.30. Conditions include support around RMB 21.35–21.50, turnover remaining within the recent range of approximately RMB 25 million–RMB 60 million, and no major new negative news or sharp sector-wide weakness. If support holds, the share price may fluctuate repeatedly around RMB 22.
• Weak downside movement (medium heuristic subjective weight, approximately 30%; not a statistical probability): Focus on a price range of RMB 19.80–21.35. Conditions include a decisive closing break below RMB 21.35, turnover expanding above RMB 60 million for consecutive sessions, continued main-fund net outflows, or simultaneous weakness in the medical-device and pharmaceutical sectors. If support around RMB 21.35 and RMB 21.46 is breached on high volume, the price could move toward the RMB 20 round-number level and the previous low of RMB 19.83.
• Stronger rebound (relatively low heuristic subjective weight, approximately 10%–20%; not a statistical probability): Focus on a price range of RMB 22.30–23.25. Conditions include the share price reclaiming the MA10, MA20 and Bollinger middle band around RMB 22.13, daily turnover reaching at least RMB 70 million and subsequently holding above RMB 22.30. A further break above RMB 22.80 would strengthen confirmation of the rebound. RMB 22.80–23.25 is the resistance zone formed by the Bollinger upper band and recent highs.

③ Capital and Liquidity Background

As of September 11, 2026, the turnover ratio was 0.53% and turnover was approximately RMB 46 million. Turnover over the past 20 trading days was approximately RMB 18 million–RMB 59 million, with a normal level of approximately RMB 25 million–RMB 35 million and a high-volume level of approximately RMB 46 million–RMB 59 million. The top-10 free-float shareholder concentration data were as of March 31, 2026, with aggregate holdings of approximately 86.20%, mainly comprising the controlling shareholder, related companies and industrial investment entities. During the same period, the visible combined holdings of public funds and insurance funds were approximately 0.67%, while institutional shareholders collectively accounted for approximately 1.35%. The shareholder-structure data are lagged, and actual holdings may have changed by September 11, 2026. High nominal concentration and relatively limited active trading float, combined with a low turnover ratio, could lead to discontinuous trading or wider bid-ask spreads in the short term. The number of shareholders was approximately 10,100 as of June 30, 2026, up 516 from March 31, 2026, also indicating a somewhat more dispersed static shareholding structure than at the end of the first quarter. However, this should not be regarded as a real-time measure.

A measurable volume signal would be a daily turnover of at least RMB 70 million, maintained above approximately RMB 60 million for two consecutive trading days, together with the share price reclaiming RMB 22.13. This could indicate a clear increase in short-term capital participation. If volume expands while the share price continues to fall below RMB 21.35, the signal would be closer to high-volume distribution or risk release.

④ Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Observation framework, not a trading instruction: Monitor whether the RMB 21.35–21.50 support zone holds; if it fails, observe the strong-support zone at RMB 19.80–20.20.
• Observation framework, not a trading instruction: Monitor whether the MA10, MA20 and Bollinger middle band around RMB 22.13 can be reclaimed.
• Observation framework, not a trading instruction: Monitor the RMB 22.80–23.25 resistance zone and whether a breakout is accompanied by a simultaneous increase in turnover.
• Observation framework, not a trading instruction: Monitor whether turnover can rise from the recent normal range of approximately RMB 20 million–RMB 60 million to above RMB 70 million and remain there for at least two trading days.

The above scenario analysis is based on closing data, historical prices and technical indicators as of September 11, 2026. Short-term share prices may also be affected by news, liquidity, broader market conditions and other factors. Technical indicators have inherent lags and limitations. This analysis does not guarantee future performance and does not constitute a buy or sell recommendation. Investors should independently assess the latest market information and bear investment risks themselves.

6. Industry Structure and Competitor Analysis

6.1 Industry Overview

Demand in China’s orthopaedic medical-device industry has a degree of rigidity and is driven mainly by population aging, degenerative bone and joint diseases, osteoporosis and sports injuries. The industry spans materials science, biomechanics, machining, medicine and clinical applications. Product development, registration, clinical validation and production quality systems have relatively high barriers to entry. Volume-based procurement is reshaping the competitive dynamics. Companies are competing less on product prices and channel coverage and more on cost control, supply capabilities, the number of registration certificates, clinical services and product portfolios.

6.2 Competitive Landscape

• International manufacturers include Johnson & Johnson, Stryker, Medtronic, Zimmer Biomet and Smith & Nephew. Their strengths include long-term R&D accumulation, global brands, products for complex procedures and coverage of high-end hospitals.
• Domestic integrated companies include Weigao Orthopaedic, Double Medical (大博医疗), Chunli Medical and AK Medical. They generally have relatively complete product lines, domestic channels and the ability to respond to volume-based procurement.
• Companies focused on specific segments include Kyphoplasty Medical and Sanyou Medical, which generally have strong competitiveness in segments such as minimally invasive spine, vertebroplasty, trauma or sports medicine.
• Volume-based procurement is promoting industry consolidation and domestic substitution, but industry clearing and market-share restructuring remain slow, and a fully stable industry structure has not yet formed.
• Competitors’ product portfolios overlap. Companies have different revenue mixes across spine, trauma, joints, sports medicine and intelligent equipment. Accordingly, comparable companies may be comparable businesses or partial direct competitors, and do not necessarily compete on a fully homogeneous basis across every product line.

6.3 Major Competitors

Compared with specialist competitors, Weigao Orthopaedic covers spine, trauma, joints, sports medicine, tissue repair and intelligent equipment, giving it stronger integrated-platform attributes. Compared with international manufacturers, its advantages lie mainly in domestic product lines, channel resources, response to volume-based procurement and supply capabilities. The traditional implant business remains affected by procurement price cuts. Future competitiveness and earnings recovery will depend more on expansion of high-margin tissue-repair and biomaterials businesses, growth in intelligent equipment and minimally invasive spine products, product-mix upgrades, cost control and domestic substitution in the supply chain. Statements regarding industry ranking, market share and being a “leading national platform company” are either the company’s own assessments or require analysis based on specific product categories; they should not be used to infer that the company ranks first across all orthopaedic segments.

7. Risk Factors

• Orthopaedic volume-based procurement and renewal policies may continue to reduce prices of traditional spine, trauma and joint implant products. Revenue from this business declined 3.76% year on year in 2025, already showing a “volume-for-price” pattern in which sales volume increased while revenue declined. Continued price pressure could constrain revenue and gross-margin recovery.
• Temporary fluctuations in domestic terminal clinical surgery volumes in the first half of 2026 caused revenue to decline 4.93% year on year and net profit attributable to shareholders to decline 6.85%. If surgery volumes recover more slowly than expected, the growth of functional repair, sports medicine, intelligent equipment and traditional implants may all be affected.
• The company relies heavily on distributor channels, with distributor revenue accounting for approximately 91.3% of revenue from principal operations in 2025. Hospital payment cycles, delivery systems, channel rebates and post-procurement price management may cause fluctuations in collections and channel profits. Net cash flow from operating activities declined 24.59% year on year in the first half of 2026.
• Functional repair and tissue regeneration has a high gross margin but accounts for approximately 28.5% of revenue. Earnings improvement depends to some extent on the continued growth of this business and product-mix upgrades. If growth in high-margin businesses slows, overall profitability may come under pressure.
• The company acquired 55% of Suzhou Jisibai’er and included it in consolidated statements in February 2026, but the target reduced the company’s first-half 2026 net profit by RMB 3.4541 million. If operating losses, synergies or earnings improvement fall short of expectations, acquisition-integration and goodwill-impairment risks may arise.
• The postponement and reassessment of certain fundraising projects may affect the construction of the R&D center, registration of new products, commercialization of R&D results and capacity planning. Some fundraising proceeds have also been used for the Jisibai’er acquisition and capital increase, and the results of the project adjustments require further validation.
• The company’s high-end medical titanium, implant-grade PEEK, special ceramics and joint-prosthesis blanks are subject to high technical and certification requirements, and some suppliers will be difficult to replace in the short term. Adverse changes in supply security, material prices or the pace of domestic substitution could affect production costs and supply stability.
• As of September 11, 2026, the share price was below the short-term moving averages, while September 11 saw a high-volume decline and main-fund net outflow. If support around RMB 21.35 fails, the technical picture could lead to a further test of RMB 19.80–20.20. This technical scenario is affected by market sentiment, liquidity and pharmaceutical-sector performance and should not be regarded as a definitive forecast.

8. Conclusion and Outlook

Weigao Orthopaedic has an integrated product platform covering spine, trauma, joints, sports medicine, intelligent equipment and tissue repair. Its traditional implant business provides a strong scale base, while tissue repair and regeneration and intelligent equipment are growing relatively quickly. If clinical surgery volumes recover in the second half, the impact of volume-based procurement stabilizes, and high-margin businesses and minimally invasive spine products continue to grow, the company still has room to improve margins and earnings growth. Institutional average forecasts put 2026–2028 net profit attributable to shareholders at approximately RMB 322 million, RMB 386 million and RMB 453 million, respectively. However, these forecasts were mainly issued before the 2026 interim report and require validation against subsequent operating data.

The current fundamentals also face short-term constraints, including year-on-year declines in revenue and profit, lower operating cash flow and continued price pressure on traditional implants. The Jisibai’er acquisition has been consolidated, but the target had a negative impact on the company’s first-half 2026 net profit. The postponed fundraising projects, acquisition synergies and goodwill impairment remain areas to monitor. The quality of future growth will depend on whether new businesses can contribute revenue and profit, and whether revenue growth can offset the impact of procurement price cuts and product-mix changes.

The share price is currently technically weak in the short term. Whether support at RMB 21.35–21.50 holds and whether the moving-average resistance around RMB 22.13 can be reclaimed may provide technical feedback on the market’s response to changes in earnings and expectations. However, technical indicators cannot replace fundamental analysis of volume-based procurement policies, surgery volumes, cash flow and acquisition integration.

Data Sources

• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: STAR Market Listing Announcement for Initial Public Offering_Sina Finance_Sina.com
• Summary of the 2025 Annual Report of Shandong Weigao Orthopaedic Device Co., Ltd.|Shanghai Securities News
• Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited Accept No Responsibility for the Contents of This Announcement
• https://static.sse.com.cn/stock/disclosure/announcement/c/202010/000559_20201012_N75G.pdf
• Regulatory Inquiry Letter on Periodic Report Information Disclosure Regarding Shandong Weigao Orthopaedic Device Co., Ltd.
• Shandong Weigao Orthopaedic Device Co., Ltd.
• Announcement of Shandong Weigao Orthopaedic Device Co., Ltd.’s Response to the Inquiry Letter on the 2023 Annual Report|Shanghai Securities News
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: 2025 Annual Report_Sina Finance_Sina.com
• 2025 Annual Report of Shandong Weigao Orthopaedic Device Co., Ltd.
• Weigao Orthopaedic (688161)_Financial Indicators_Sina Finance_Sina.com
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: 2021 Annual Report of Shandong Weigao Orthopaedic Device Co., Ltd. (Revised)_Sina Finance_Sina.com
• 〖Industry Analysis〗2024 Competitive Landscape and Market-Share Analysis of China’s Orthopaedic Implant Medical-Device Industry: Relatively Low Domestic Market Concentration_Qianzhan Industry Research Institute
• Comparison of Product Portfolios of the Company and Comparable Listed Companies in the Orthopaedic Implant Medical-Device Industry
• Summary of the 2026 Interim Report of Shandong Weigao Orthopaedic Device Co., Ltd.
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: Summary of the 2026 Interim Report_Sina Finance_Sina.com
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: 2026 Interim Report_Sina Finance_Sina.com
• Weigao Orthopaedic (688161) 2026 Interim Report Analysis: Net Profit Down 6.85% Year on Year, Accounts Receivable Increased_Stock Channel_Securities Star
• Weigao Orthopaedic (688161) Earnings Forecast_F10_Tonghuashun Financial Services
• Weigao Orthopaedic (688161) Earnings Forecast_F10_Tonghuashun Financial Services
• Weigao Orthopaedic (688161) Latest Stock Price, Real-Time Chart, Stock Analysis and Forecast_Investing.com
• Weigao Orthopaedic (688161) Latest Developments_F10_Tonghuashun Financial Services
• Weigao Orthopaedic (688161.SH) Stock Quotes_Historical Data_Main-Fund Flow_Dabolang Data
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: 2026 Interim Report_Sina Finance_Sina.com
• Securities Code: 688161
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: Announcement on Participating in the 2026 First-Half Collective Earnings Briefing for the Medical Device and Medical Equipment Industry on the STAR Market_Sina Finance_Sina.com
• Weigao Orthopaedic (688161) Company Announcements_Sina Finance_Sina.com
• Weigao Orthopaedic (688161): Cash Management Using Partially Idle Internal Funds_CFi.CN
• Weigao Orthopaedic (688161) Trading Notices_Securities Star
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: Announcement on Response to the Inquiry Letter on the 2025 Annual Report_Sina Finance_Sina.com
• Weigao Orthopaedic (688161)_Company Announcements_Weigao Orthopaedic: Announcement on Changing Certain Fundraising Projects, Acquiring Equity in Suzhou Jisibai’er Medical Technology Co., Ltd. and Injecting Capital into It_Sina Finance_Sina.com
• Weigao Orthopaedic (688161) Stock Information_Data Platform
• Weigao Orthopaedic (688161.SH) Stock Quotes_Historical Data_Main-Fund Flow_Dabolang Data

This report was automatically retrieved, compiled and generated by AI based on publicly available information. The information is current as of the close on September 11, 2026; prices, trading volumes and technical indicators may differ across data platforms, and moving averages, MACD, RSI and Bollinger Bands are based on unadjusted daily data. There may be differences in timeliness. Specific data should be based on the company’s official announcements and authoritative data terminals. This report is for information organization and research reference only, does not constitute investment advice of any kind, and investors should make independent judgments and bear investment risks themselves.